Nutraceuticals for Age-Related Macular Degeneration: Formulation Optimization Focused on Safety

Age-related macular degeneration (AMD) is a multifactorial disease, with oxidative stress as a main pathogenetic factor in the development and progression. Large clinical trials have shown that the additional intake of vitamins and minerals in high doses reduce the risk progression to advanced wet AMD by 25 %. Some of these powerful antioxidants are not synthesized in the human body and can only be obtained with food as part of dietary supplements. However, patients with AMD, belonging to the older age group, often have comorbid conditions, for which they are used to take appropriate drug and vitamin therapy for a long time, as well as they have malnutrition of varying severity. Additional intake of high doses of ophthalmic vitamin-mineral complexes can lead to side effects due to overdose and possible disorders of drug absorption due to concomitant pathology. The article presents the results of the AREDS 2 study and a number of other clinical trials that studied long-term intake of vitamins and minerals in dosages similar to the AREDS 1 formula, containing vitamin C (500 mg), vitamin E (400 international units), beta-carotene (15 mg), zinc (80 mg as zinc oxide) and copper (2 mg as copper oxide). The cited works show that long-term intake of high dosages of some vitamins in elderly patients with severe concomitant diseases and a history of smoking can lead to undesirable consequences for the eye and other body systems. Potential side effects include an increased risk of glaucoma and cataract, an increased risk of prostate cancer in healthy men, an increased risk of lung cancer in former smokers, and an increased risk of cardiovascular disease in postmenopausal women with diabetes. Thus, high dosages of vitamins and minerals in nutraceuticals should be administered with great caution, and a reduction in dosages to the recommended intake rates when switching to long-term intake may be considered. One of the possibilities for increasing the bioavailability of active substances in the composition of dietary supplements can be a microencapsulation.

1. Wong W.L., Su X., Li X., Cheung C.M., Klein R. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):106–116. DOI: 10.1016/S2214-109X(13)70145-1

2. World report on vision. World Health Organization. Published October 8, 2019. Accessed November 2, 2019. who.int/publications-detail/world-report-on-vision

3. Ammar M.J., Hsu J., Chiang A., Ho A.C., Regillo C.D. Age-related macular degeneration therapy: a review. Curr Opin Ophthalmol. 2020;31(3):215–221. DOI: 10.1097/ICU.0000000000000657

4. Brown D.M., Michels M., Kaiser P.K., Heier J.S., Sy J.P., Ianchulev T.; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57–65.е5. DOI: 10.1016/j.ophtha.2008.10.018

5. Heier J.S., Brown D.M., Chong V., Korobelnik J.F., Kaiser P.K., Nguyen Q.D. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. DOI: 10.1016/j.ophtha.2012.09.006

6. Skaat A., Chetrit A., Belkin M., Kinori M., Kalter-Leibovici O. Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol. 2012;153(2):214–221. e1. DOI: 10.1016/j.ajo.2011.08.035

7. Budzinskaya M.V., Pogoda T.V., Generozov E.V. Contemporary pharmacogenetic approaches to the treatment of age related macular degeneration. Annals of Ophthalmology = Vestnik oftal’mologii. 2013;129(5):128–135 (In Russ.).

8. Pedanova E.K., Doga A.V. Treatment of polypoid choroidal vasculopathy: photodynamic therapy, anti-VEGF therapy, or their combination? Review study. Оphthalmology in Russia = Oftal’mologiya. 2019;16(2):151–158 (In Russ.). DOI: 10.18008/1816-5095-2019-2-151-158

9. Tisi A., Feligioni M., Passacantando M., Ciancaglini M., Maccarone R. The Impact of Oxidative Stress on Blood-Retinal Barrier Physiology in Age-Related Macular Degeneration. Cells. 2021;10(1):64. DOI: 10.3390/cells10010064

10. Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. Control Clin Trials. 1999;20(6):573–600. DOI: 10.1016/s0197-2456(99)00031-8

11. Chew E.Y., Clemons T.E., Agrón E., Sperduto R.D., Sangiovanni J.P., Kurinij N., Davis M.D.; Age-Related Eye Disease Study Research Group. Long-Term Effects of Vitamins C, E, Beta-Carotene and Zinc on Age-Related Macular Degeneration. AREDS Report No. 35. Ophthalmology. 2013;120(8):1604–1611.e4. DOI: 10.1016/j.ophtha.2013.01.021

12. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417–1436. DOI: 10.1001/archopht.119.10.1417

13. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19):2005–2015. DOI: 10.1001/jama.2013.4997

14. Turusheva A.V., Moiseeva I.E. Malnutrition in middle and late adulthood. Russian family doctor = Rossiyskiy semeynyy vrach. 2019;23(1):5–15 (In Russ.). DOI: 10.17816/RFD201915-15

15. Khavkin A.I., Komarova O.N. Malabsorption and prospects for the use of fat-soluble vitamins in liver diseases. Experimental and Clinical Gastroenterology = Eksperimental’naya i klinicheskaya gastroenterologiya. 2016;7(131):86–94 (In Russ.).

16. Meltzer H.M., Aro A., Andersen N.L., Koch B., Alexander J. Risk analysis applied to food fortification. Public Health Nutr. 2003;6(3):281–291. DOI: 10.1079/PHN2002444

17. Soni M.G., Thurmond T.S., Miller E., Spriggs T., Bendich A., Omaye S.T. Safety of vitamins and minerals: controversies and perspective. Toxicol Sci. 2010;118(2):348–355. DOI: 10.1093/toxsci/kfq293

18. Omenn G.S., Goodman G.E., Thornquist M.D., Balmes J. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334(18):1150–1155. DOI: 10.1056/NEJM199605023341802

19. Boehm F., Edge R., Truscott T.G. Anti- and pro-oxidative mechanisms comparing the macular carotenoids zeaxanthin and lutein with other dietary carotenoids — a singlet oxygen, free-radical in vitro and ex vivo study. Photochem Photobiol Sci. 2020;19(8):1001–1008. DOI: 10.1039/d0pp00120a

20. Whitehead A.J., Mares J.A., Danis R.P. Macular pigment: a review of current knowledge. Arch Ophthalmol. 2006;124(7):1038–1045. DOI: 10.1001/archopht.124.7.1038

21. Loane E., Kelliher C., Beatty S., Nolan J.M. The rationale and evidence base for a protective role of macular pigment in age-related maculopathy. Br J Ophthalmol. 2008;92(9):1163–1168. DOI: 10.1136/bjo.2007.135566

22. Trieschmann M., Beatty S., Nolan J.M., Hense H.W., Heimes B., Austermann U., Fobker M., Pauleikhoff D. Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study. Exp Eye Res. 2007;84(4):718–728. DOI: 10.1016/j.exer.2006.12.010

23. Neelam K., Hogg R.E., Stevenson M.R., Johnston E., Anderson R., Beatty S., Chakravarthy U. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiol. 2008;15(6):389–401. DOI: 10.1080/09286580802154275

24. Gorusupudi A., Nelson K., Bernstein P.S. The Age-Related Eye Disease 2 Study: Micronutrients in the Treatment of Macular Degeneration. Adv Nutr. 2017;8(1):40–53. DOI: 10.3945/an.116.013177

25. Clarke M.W., Burnett J.R., Croft K.D. Vitamin E in human health and disease. Crit Rev Clin Lab Sci. 2008;45(5):417–450. DOI: 10.1080/10408360802118625

26. Hickman I., Macdonald G. Is vitamin E beneficial in chronic liver disease? Hepatology. 2007;46(2):288–290. DOI: 10.1002/hep.21834

27. Ledesma M.C., Jung-Hynes B., Schmit T.L., Kumar R., Mukhtar H., Ahmad N. Selenium and vitamin E for prostate cancer: Post-SELECT (Selenium and Vitamin E Cancer Prevention Trial) status. Mol Med. 2011;17:134–143. DOI: 10.2119/molmed.2010.00136

28. Zheng Selin J., Rautiainen S., Lindblad B.E., Morgenstern R., Wolk A. High-dose supplements of vitamins C and E, low-dose multivitamins, and the risk of age-related cataract: a population-based prospective cohort study of men. Am J Epidemiol. 2013;177(6):548–555. DOI: 10.1093/aje/kws279

29. Tanumihardjo S.A., Li J., Dosti M.P. Lutein absorption is facilitated with cosupplementation of ascorbic acid in young adults. J Am Diet Assoc. 2005;105(1):114–118. DOI: 10.1016/j.jada.2004.10.011

30. Gromova O. Vitamin C (review). Aesthetic medicine = Esteticheskaya medicina. 2007;VI(1):13–24 (In Russ.).

31. Rinninella E., Mele M.C., Merendino N., Cintoni M. The role of Diet, Micronutrients and the Gut Microbiota in Age-Related Macular Degeneration: New Perspectives from the Gut — Retina Axis. Nutrients. 2018;10(11):1677. DOI: 10.3390/nu10111677

32. Braakhuis A.J., Donaldson C.I., Lim J.C., Donaldson P.J. Nutritional Strategies to Prevent Lens Cataract: Current Status and Future Strategies. Nutrients. 2019;11(5):1186. DOI: 10.3390/nu11051186

33. Lee D.H., Folsom A.R., Harnack L., Halliwell B., Jacobs D.R. Jr. Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? Am J Clin Nutr. 2004;80(5):1194–1200. DOI: 10.1093/ajcn/80.5.1194

34. Sarmento R.A., Silva F.M., Sbruzzi G., Schaan B.D., Almeida J.C. Antioxidant micronutrients and cardiovascular risk in patients with diabetes: a systematic review. Arq Bras Cardiol. 2013;101(3):240–248. DOI: 10.5935/abc.20130146

35. Kolenko V.,Teper E.,Kutikov A., Uzzo R. Zinc and zinc transporters in prostate carcinogenesis. Nat Rev Urol. 2013;10(4):219–226. DOI: 10.1038/nrurol.2013.43

36. Zhang Y., Coogan P., Palmer J.R., Strom B.L., Rosenberg L. Vitamin and mineral use and risk of prostate cancer: the case-control surveillance study. Cancer Causes Control. 2009;20(5):691–698. DOI: 10.1007/s10552-008-9282-y

37. Hambidge M. Underwood Memorial Lecture: human zinc homeostasis: good but not perfect. J Nutr. 2003;113(5) (suppl 1):1438S–1442S. DOI: 10.1093/jn/133.5.1438S

38. Zackular J., Moore A.J., Jordan A.T., Juttukonda L.J. Dietary Zinc Alters the Microbiota and Decreases Resistance to Clostridium difficile Infection. Nat Med. 2016;22(11):1330–1334. DOI: 10.1038/nm.4174

39. Reshetnik L.A., Parfenova E.O. Biogeochemical and clinical significance of selenium for human health. Trace elements in medicine. 2001;2(2):2–8 (In Russ.).

40. Tretyak L.N., Gerasimov E.M. Specificity of the influence of selenium on the human and animal organism (in relation to the problem of creating selenium-containing food products). Annals of Orenburg State University = Vestnik Orenburgskogo gosudarstvennogo universiteta. 2007;12(79):136–145 (In Russ.).

41. Clark L.C., Combs G.F. Jr, Turnbull B.W., Slate E.H. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996;276(24):1957–1963.

42. Conley S.M., McKay B.S., Gandolfi, A.J., Stamer W.D. Alterations in human trabecular meshwork cell homeostasis by selenium. Exp Eye Res. 2006;82(4):637–647. DOI: 10.1016/j.exer.2005.08.024

43. Stranges S., Marshall J.R., Natarajan R., Donahue R.P. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med. 2007;147(4):217–223. DOI: 10.7326/0003-4819-147-4-200708210-00175

44. Bleys J., Navas-Acien A., Stranges S., Menke A., Miller E.R. 3rd, Guallar E. Serum selenium and serum lipids in US adults. Am J Clin Nutr. 2008;88(2):416–423. DOI: 10.1093/ajcn/88.2.416

45. Kodentsova V.M. Grading of vitamin intake levels: possible risks of excessive intake. Voprosy Pitaniya = Voprosy pitaniya. 2014;83(3):41–51 (In Russ.). DOI: 10.24411/0042-8833-2014-00028

46. Evans M., Beck M., Elliott J., Etheve S., Roberts R., Schalch W. Effects of formulation on the bioavailability of lutein and zeaxanthin: a randomized, doubleblind, cross-over, comparative, single-dose study in healthy subjects. Eur J Nutr. 2013;52(4):1381–1391. DOI: 10.1007/s00394-012-0447-9

47. Tomaro-Duchesneau C., Saha S., Malhotra M., Kahouli I., Prakash S. Microencapsulation for the Therapeutic Delivery of Drugs, Live Mammalian and Bacterial Cells, and Other Biopharmaceutics: Current Status and Future Directions. J Pharmac. 2013;2013:103527. DOI: 10.1155/2013/103527

48. Kostic D., White W.S., Olson J.A. Intestinal absorption, serum clearance, and interactions between lutein and beta-carotene when administered to human adults in separate or combined oral doses. Am J Clin Nutr. 1995;62(3):604–610. DOI: 10.1093/ajcn/62.3.604

49. Neroev V.V. Russian observational epidemiological non-interventional study of patients with wet age-related macular degeneration. Russian ophthalmological journal = Rossiyskiy oftal’mologicheskiy zhurnal. 2011;4(2):4–9 (In Russ.).

50. Filippova O.V. Selecting drug formulation for the treatment and prevention of retinal disorders. Russian Medical Journal. Clinical Ophthalmology = Rossiyskiy medicinskiy zhurnal. Klinicheskaya oftal’mologiya. 2019;19(4):211–216 (In Russ). DOI: 10.32364/2311-7729-2019-19-4-211-216